Nrx pharmaceuticals (nasdaq:nrxp) presents landmark trial of nrx-101 in suicidal bipolar depression at the american society of clinical psychopharmacology annual meeting: nrx-101 is the first oral antidepressant demonstrated to reduce suicidality in bipolar depression

Poster presentation of "a randomized, double-blind controlled comparison of nrx-101 (d-cycloserine/lurasidone) to lurasidone for adults with bipolar depression and subacute suicidal ideation or behavior" nrx-101 demonstrated a similar antidepressant effect (madrs reduction ~50%) compared to lurasidone, the standard of care drug nrx-101 demonstrated a 58% relative reduction in time to sustained remission from suicidality (p=.05) compared to lurasidone nrx-101 demonstrated a 76% reduction in symptoms of akathisia (p=0.03), a side effect linked to suicide, compared to lurasidone this represents the second trial of nrx-101 demonstrating reduction in suicidality and akathisia associated with nrx-101 compared to lurasidone radnor, pa. , may 28, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", "nrx", the "company"), a clinical stage pharmaceutical company, today announced presentation of its phase 2b/3 trial of nrx-101, entitled  "a randomized, double-blind controlled comparison of nrx-101 (d-cycloserine/lurasidone) to lurasidone for adults with bipolar depression and subacute suicidal ideation or behavior" at the american society of clinical psychopharmacology (ascp) in miami beach, fl.
NRXP Ratings Summary
NRXP Quant Ranking